3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
Public ClinicalTrials.gov record NCT00718861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis
Study identification
- NCT ID
- NCT00718861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Zoledronic acid Drug
Drug
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Mar 31, 2013
- Completion
- Mar 31, 2013
- Last update posted
- Oct 8, 2014
2008 – 2013
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | San Diego | California | 92103-6204 | — |
| Novartis Investigative Site | Lakewood | Colorado | 80227 | — |
| Novartis Investigative Site | Gainesville | Georgia | 30501 | — |
| Novartis Investigative Site | Indiamapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Bangor | Maine | 04401 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87106 | — |
| Novartis Investigative Site | Fargo | North Dakota | 58103 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15261 | — |
| Novartis Investigative Site | Richmond | Virginia | 23249 | — |
| Novartis Investigative Site | Seattle | Washington | 98144 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00718861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00718861 live on ClinicalTrials.gov.